Lilly's weight-loss treatment Zepbound becomes first FDA-approved drug for sleep apnea
The U.S. Food and Drug Administration on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug greenlighted to directly treat patients with the common sleeping disorder.
2don MSN
We recently compiled a list of the 6 Stocks Jim Cramer Talked About This Week. In this article, we are going to take a look ...
What Eli Lilly ( LLY -0.05%) is doing is far more impressive. The company has been increasing its dividend at a high rate, ...
Two Dearborn County high school seniors recently learned they are the 2025 recipients of a prestigious Lilly Endowment ...
The updates from clinical trials of Eli Lilly's competitors in the obesity market were largely underwhelming this year. See ...
Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection ...
The Village of Pleasant Prairie Plan Commission on Monday approved the preliminary site and operational plans for the ...
Eli Lilly just gave investors several reasons to cheer.
Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Akash Tewari has given his Buy rating due to a combination of factors including Eli Lilly & Co’s strategic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback